HLS potent, novel inhibitor of fibrinolytic hemorrhage- phase II
Ended Project Grant Awarded Last action
- Award ID
- R44HL137514
- Recipient
-
Translational Sciences Inc. UEI EFQDNXDDTBM4
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,812,000
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Originally
- Place of performance
- Arizona, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,067,767 | |
| Amendment | $1,321,017 | |
| Amendment | $0 | |
| Original award | $423,216 |
Quick answers
Who received award R44HL137514?
R44HL137514 was awarded to Translational Sciences Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on April 5, 2017.
How much is award R44HL137514 worth?
$2,812,000 has been obligated on R44HL137514.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award